Results 101 to 110 of about 291,220 (220)

Current advances in 2025: A critical review of selected topics by the Association for the Advancement of Blood and Biotherapies (AABB) Clinical Transfusion Medicine Committee

Transfusion, EarlyView.
Nabiha H. Saifee, Jennifer Andrews, Mary Berg, Stella T. Chou, Mischa Covington, Elizabeth P. Crowe, Ruchika Goel, Juliana A. Guarente, Tina Ipe, Jeremy W. Jacobs, Jessica Jacobson, Cyril Jacquot, Jenna Khan, Thane A. Kubik, Theodros Mamo, Michael F. Murphy, Kerry O'Brien, Monica B. Pagano, Anil K. Panigrahi, Jacqueline N. Poston, Scott E. Potter, Simon J. Stanworth, Moritz Stolla, Alyssa Ziman, Ryan A. Metcalf   +24 more
wiley   +1 more source

Sepsis: Epidemiology, Pathophysiology, and Management

MedComm, Volume 7, Issue 11, November 2026.
Sepsis remains a major global health burden characterized by substantial geographical heterogeneity and a considerable disease burden in China. Its pathophysiology reflects an interconnected network involving excessive inflammation, oxidative stress, immune imbalance and immunoparalysis, mitochondrial damage, endothelial injury, gut dysbiosis ...
Guang‐Tao Pan, Yu Deng, Lin‐Rui Ma, Yu‐Tong Li, Yu Qian, Yi‐Hua Ma, Hai‐Wei Rao, Yi‐Zhun Zhu, Pei‐Yu Yan   +8 more
wiley   +1 more source

The Use Of A Potential Novel Tool In Virtual Crossmatching For Platelet Transfusion In Platelet Refractoriness

, 2016
Background and Objectives: Transfusion support for immune-mediated platelet refractoriness (PR) is clinically challenging, technically laborious and costly.
Sousa, L C D M, Castro, V, do Monte, S J H, Gonçalez, A C, Barjas-Castro, M L, Bub, C B   +5 more
core   +2 more sources

Alloimmune platelet refractoriness [PDF]

En la actualidad, la transfusión de plaquetas, es considerado el tratamiento estándar en pacientes con trombocitopenia, siendo el concentrado plaquetario, el hemocomponente transfundido con mayor frecuencia.
Ancajima Ballena, Maria Elena
core  

Changes in inflammatory responses and autophagy during apheresis platelet preservation and their correlation with platelet transfusion refractoriness in patients with acute lymphoblastic leukemia. [PDF]

Biomol Biomed, 2023
Li Y, Song Z, Sun X, Tang J, Zhou X.
europepmc   +1 more source

Feasibility and Safety of Venetoclax for Cytoreduction During Induction Therapy in Newly Diagnosed Acute Promyelocytic Leukemia

European Journal of Haematology, Volume 117, Issue 5, Page 1258-1264, November 2026.
ABSTRACT Objective This study aimed to evaluate the feasibility and safety of venetoclax as a cytoreductive strategy during induction therapy in newly diagnosed acute promyelocytic leukemia (APL), and to provide an exploratory description of its early efficacy.
Yu Wang, Rong Xiao, Xiaobing Huang, Yi Xiao   +3 more
wiley   +1 more source

Dose‐Adjusted Treatment With 7‐Day Venetoclax Plus Azacitidine or Decitabine in Patients With Acute Myeloid Leukaemia

European Journal of Haematology, Volume 117, Issue 5, Page 1358-1368, November 2026.
ABSTRACT Acute myeloid leukaemia (AML) in older or unfit patients is commonly treated with hypomethylating agents (HMA) plus venetoclax (VEN), but prolonged VEN exposure often causes substantial haematological toxicity. We retrospectively analysed 61 elderly AML patients treated with HMA + VEN for 7 (7d), 14 (14d) or > 14 days (> 14d) per cycle.
Laurenz Steiner, Lina S. Silva‐Bermudez, Mahmoud Ghazal, Mohammed Abba, Catharina Gerhards, Georgia Metzgeroth, Alice Fabarius, Stefan Klein, Sebastian Kreil, Nanni Schmitt, Patrick Wuchter, Wolf‐Karsten Hofmann, Alexander Streuer   +12 more
wiley   +1 more source

A case of platelet transfusion refractoriness in a CD36-negative patient with acute myeloid leukemia: Diagnostic and therapeutic management. [PDF]

Transfusion, 2022
Pedini P, Hicheri Y, Bertand G, Dettori I, Basire A, Lazaygues C, Chabrières C, Perrin C, Pascal J, Chiaroni J, Renac V, Ladaique P, Vey N, Picard C.   +13 more
europepmc   +1 more source

Evaluating the Efficacy of Cytokine‐Directed Therapies in the Management of VEXAS Syndrome

ACR Open Rheumatology, Volume 8, Issue 10, October 2026.
Objective To evaluate the efficacy of cytokine‐directed therapies in VEXAS (vacuoles, E1 enzyme, X‐linked, autoinflammatory somatic) syndrome using previously proposed treatment response criteria. Methods All patients with genetically confirmed VEXAS syndrome who received targeted therapies with JAK inhibitors (JAKi), tumor necrosis factor α inhibitors
Daniel Montes, Hannah E. Langenfeld, Andrew C. Hanson, Cynthia S. Crowson, Mrinal M. Patnaik, Ronald S. Go, Kambiz Kalantari, Yael Kusne, Terra Lasho, Abhishek A. Mangaonkar, Horatiu Olteanu, Kaaren K. Reichard, Megan M. Sullivan, David S. Viswanatha, Kenneth J. Warrington, Matthew J. Koster   +15 more
wiley   +1 more source

Current Status of and Global Trends in Platelet Transfusion Refractoriness From 2004 to 2021: A Bibliometric Analysis. [PDF]

Front Med (Lausanne), 2022
Liu Y, Zhang Y, Chen D, Fu Y.
europepmc   +1 more source